二甲双胍对糖尿病并发肾癌患者生存结果影响的Meta分析  

A Meta-analysis on the effect of metformin on the survival in diabetic patients with renal cell cancer

作　　者：宋燕燕[1] 肖晖[1] 肖慕然 向伟[1] 

机构地区：[1]武汉大学中南医院血液内科,湖北武汉430071

出　　处：《现代肿瘤医学》2017年第12期1937-1941,共5页Journal of Modern Oncology

摘　　要：目的:运用Meta分析来评估二甲双胍对糖尿病并发肾癌患者生存结果影响。方法:检索Pub Med、EMbase、CNKI等数据库,筛选并纳入相关文献,提取文献特征,采用Review Manager 5.3软件计算总的风险比(HR)及95%CI,并评价研究间的异质性、有无发表偏倚。结果:共纳入5篇队列研究。根据肾癌局部与转移的亚组分析结果显示二甲双胍对肾癌患者的PFS无显著改善作用(HR=0.78,95%CI:0.42~1.45,P=0.43)、(HR=0.98,95%CI:0.81~1.19,P=0.84),同样对CSS、OS也无显著影响(HR=0.59,95%CI:0.22~1.58,P=0.30)、(HR=0.78,95%CI:0.50~1.22,P=0.28),(HR=1.01,95%CI:0.71~1.43,P=0.96)、(HR=1.05,95%CI:0.83~1.33,P=0.68)。发表偏倚结果显示不存在发表偏倚(Begg:P=0.658;Egger:P=0.765)。结论:本项Meta分析显示二甲双胍对于肾癌患者的生存结果无显著改善作用。Objective：To evaluate the effect of metformin on survival indiabetes mellitus patients complicated with renal cell carcinoma（ RCC） by Meta-analysis.Methods：Multiple database were searched to identify studies on the association between use of metformin and survival of renal cell carcinoma.Relevant information for analysis was extracted.A random-effects model was used to calculate the pooled risk estimate and its 9 5 % confidence interval（ CI）.Heterogeneity across studies and publication bias were tested.Results：5 cohort studies were included.Subgroup analysis by the localized renal cancer and the metastatic showed that there was no significant improvement in PFS（ HR=0.78,95% CI：0.42~1.45,P=0.43）,（ HR=0.98,95% CI：0.81~1.19,P=0.84）,but also had no significant effect on CSS and OS（ HR=0.59,95% CI：0.22~1.58,P=0.30）,（ HR=0.78,95% CI：0.50~1.22,P =0.28）,（ HR=1.01,95% CI：0.71~1.43,P=0.96）,（ HR=1.05,95% CI：0.83~1.33,P=0.68）.The publication bias showed no publication bias（ Begg,P=0.658; Egger,P=0.765）.Conclusion：This Meta-analysis showed that metformin did not significantly improve survival outcomes in patients with renal cell carcinoma.

关 键 词：二甲双胍 糖尿病 肾癌 生存率 META分析 

分 类 号：R737.11[医药卫生—肿瘤]